Rituximab Articles
Survey finds one third of RA patients hide extent of symptoms
15 October 2007
US biogenerics mart to reach $2B by 2016
17 September 2007
Biogen forecasts 2007 sales growth of 16-18%, and EPS to increase 20% a year to 2010
17 September 2007
US orphan status for Cephalon's Treanda for CLL
10 September 2007
NICE accepts drugmaker case for RA drug
3 September 2007
Cell Therapeutics buys Zevalin from Biogen Idec for $10M, with up to $20M extra plus milestones
3 September 2007
Cancer, RA drugs boost Genentech
16 July 2007
Cephalon plans to file Treanda NDA in 3rd qtr
9 July 2007
Algeta extends R&D accord with Radium Hospital
25 June 2007
Biogen Idec share repurchase plan
4 June 2007
FDA fast-tracks Cell Thera's pixantrone
21 May 2007
Rituxan yields promising results in RRMS
14 May 2007
Biogen's 1st-qtr income climbs 7% to $131M
14 May 2007
Stock Commentary - New York week to April 23, 2007
30 April 2007
Roche 1st-qtr at top end of expectations
23 April 2007
Genentech updates of Cabilly patent re-examination
26 February 2007
Biogen Idec's 4th-qtr profit up 95% to $109M
26 February 2007
Roche posts record 2006 net profits, boosted by cancer drugs
12 February 2007
Biogen's galiximab enters Ph III cancer trial
5 February 2007
FDA issues PML warning for Rituxan
22 December 2006
GSK and Genmab to develop HuMax CD20
22 December 2006
Dynavax' TLR9 drug prolongs time-to-progression
22 December 2006
MabThera improves survival in NHL
20 November 2006
Immunomedics' epratuzumab "distinct from Rituxan"
20 November 2006
MabThera effective as repeat RA treatment
20 November 2006
Stock Commentary - New York week to Nov 6, 2006
13 November 2006
Biogen Idec's 3rd-qtr income rockets 476%
13 November 2006
Roche reports sales of $23.89B for first three qtrs of 2006, a 4.7% share of global market
23 October 2006
Genentech's 3rd-qtr GAAP net leaps 58%
16 October 2006
Less price flexibility, more innovation: the market dynamics of targeted therapeutics
16 October 2006
Zevalin in aggressive Lymphoma trial
16 October 2006
Rituxan gets FDA approval for 1st-line use in NHL
16 October 2006
NICE approves MabThera as first-line therapy for NHL
2 October 2006
Rituxan meets primary endpoint in MS trial
4 September 2006
Israeli NHI Ombudswoman's complaints report
4 September 2006
Zymogenetics starts combined IL-21 and Rituxan study
17 July 2006
MabThera gets EU go-ahead for RA and NHL
17 July 2006
BI's 1st-qtr revenues hit $611M, up 4%
8 May 2006
Roche's 1st-qtr 2006 sales rise 22%
8 May 2006
Four vice president appointments at Genentech
17 April 2006
Genentech/Biogen Idec submit Rituxan sBLA
3 April 2006
Strong in vivo data for Algeta's radioactive MAb
27 March 2006
Japan recalculates eight drug ingredients due to high sales
27 February 2006
Biogen Idec sees 8% 4th-qtr 2005 sales rise
27 February 2006
FDA approves Rituxan for NH lymphoma
20 February 2006
Favrille completes enrollment in FavId Ph III trial
6 February 2006
FDA fast-tracks Favrille's FavId
16 January 2006
Immunomedics' epratuzumab-rituximab combo in lymphoma
19 December 2005
Licensing pivotal to pharma industry evolving strategies
19 December 2005
Biogen Idec to cut 17% of jobs in response to Tysabri
19 September 2005
Roche's MabThera filed in Europe as an RA drug
12 September 2005
Roche and partners apply for expanded indication for Rituxan
22 August 2005
Biogen Idec's second-quarter EPS rises 26%
15 August 2005
Biogen Idec and PDL form alliance
8 August 2005
Roche Rx sales grow three times world rate
25 July 2005
Positive Ph II data for Schering AG's Zevalin
20 June 2005
Genta's Genasense combo sees strong efficacy data
20 June 2005
Encouraging data for MabThera in RA
20 June 2005
Millennium's Velcade: comparable to Rituxan
20 June 2005
Positive Ph II data for Schering AG's Zevalin
20 June 2005
New hope for lymphoma cancer patients
20 June 2005
Favrille's FavId Ph III enrollment on schedule
6 June 2005
Cephalon to buy Salmedix for $160M
23 May 2005
Biogen: 1st-qtr profit despite Tysabri loss
9 May 2005
Strong data for Roche/Genentech/Biogen Idec's MabThera
25 April 2005
Roche 1st-qtr sales, up 17%, beat estimates
25 April 2005
Stock Commentary - Europe
18 April 2005
UPDATE: Roche's Rituxan shows improvement in RA
18 April 2005
Immunomedics' anti-CD20 Ab effective for severe lupus
18 April 2005
Roche's MabThera to treat RA?
11 April 2005
PacMab raises fund for new cancer therapy
21 March 2005
IMS: 2004 world Rx sales growth slowest in six yrs
14 March 2005
Biogen Idec boosted by Avonex
14 February 2005
Expanded indication for GSK's Bexxar
10 January 2005
Roche's MabThera improves survival in NHL at 30 months
20 December 2004
Roche's Genentech gamble pays off
13 December 2004
Biogen's 3rd-qtr profit falls on merger costs
8 November 2004
Japan's Chugai posts nine-month results in line with forecasts
8 November 2004
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
